Tracking Body Composition Changes During Cancer Recovery With DEXA
The Question Everyone Asks First: Can a DEXA Scan Show Cancer?
If you or someone you love is navigating cancer recovery, you may have come across DEXA scanning and wondered: can a DEXA scan show cancer? It's one of the most common questions we hear, and it deserves a direct, honest answer before anything else.
A DEXA scan—dual-energy X-ray absorptiometry—is not a cancer diagnostic tool. It does not detect tumors, identify malignancies, or replace oncological imaging like CT scans, MRI, or PET scans. If you are searching for does a DEXA scan show cancer, the answer is no, not in any clinically meaningful way. DEXA is not designed for that purpose, and no responsible provider should position it that way.
What DEXA does—and does extraordinarily well—is something entirely different and, for cancer survivors, arguably just as important: it gives you a precise, clinical-grade picture of what is happening inside your body in terms of muscle mass, fat distribution, and bone mineral density. For anyone coming out the other side of chemotherapy, radiation, hormone therapy, or surgery, those three metrics are not abstract wellness numbers. They are the physical landscape of your recovery.
This article is for people in that landscape. People who have finished treatment, or are mid-treatment, and are asking: what did this do to my body, and how do I rebuild?
What Cancer Treatment Actually Does to Body Composition
Oncologists are focused on eliminating disease. That is exactly what they should be focused on. But the collateral effect of most cancer treatments on body composition is severe, well-documented, and frequently under-addressed in post-treatment care.
Here is what the research shows happens to the body during and after common cancer treatments:
Chemotherapy
Chemotherapy causes what researchers call cancer-related muscle wasting, or cachexia, in a significant percentage of patients. Even patients who do not lose visible body weight can lose substantial lean muscle mass—a phenomenon sometimes called sarcopenic obesity, where fat replaces muscle while the scale stays relatively stable. Studies have found that muscle loss during chemotherapy is independently associated with worse treatment outcomes, increased toxicity from drugs, longer recovery times, and reduced survival in some cancers.
The mechanism is multifactorial: nausea reduces caloric intake, fatigue reduces physical activity, systemic inflammation accelerates protein breakdown, and the drugs themselves can directly damage muscle tissue at the cellular level.
Hormone Therapy
Hormone-sensitive cancers—particularly breast cancer (treated with aromatase inhibitors or tamoxifen) and prostate cancer (treated with androgen deprivation therapy, or ADT)—involve treatments that suppress the very hormones that protect muscle and bone. Testosterone and estrogen are not just reproductive hormones. They are anabolic signals that tell your body to build and maintain muscle and preserve bone mineral density.
Men on ADT for prostate cancer lose an average of 2–4% of lean body mass per year while gaining visceral fat. Women on aromatase inhibitors for breast cancer experience accelerated bone density loss at rates that can parallel post-menopausal decline compressed into a shorter window. These are not minor side effects. They are body composition transformations happening in real time, and they are largely invisible to the scale.
Radiation
Radiation's effects on body composition are more localized but can be significant depending on the target area. Abdominal or pelvic radiation can affect gut absorption, indirectly limiting nutritional intake and protein synthesis. Head and neck radiation frequently disrupts the ability to eat normally for months, leading to muscle loss that persists long after treatment ends.
Surgery and Immobility
Major cancer surgery often involves weeks of restricted mobility and reduced caloric intake during recovery. Research on surgical patients consistently shows rapid muscle atrophy during immobilization—losses that can take months to reverse under ideal conditions, and may never fully reverse without intentional intervention.
Why the Scale Tells You Almost Nothing During Cancer Recovery
This is the central problem. Most cancer survivors track their recovery the way everyone tracks their health: by stepping on a scale.
The scale will tell you that you have lost 15 pounds during treatment. What it will not tell you is whether that 15 pounds was 12 pounds of muscle and 3 pounds of fat—which is catastrophic—or 3 pounds of muscle and 12 pounds of fat—which is at least directionally better. It will not tell you that your bone density has declined 8% since your last scan. It will not tell you that even though you have gained some weight back post-treatment, a disproportionate amount of it is visceral fat accumulating around your organs.
These distinctions matter enormously for how you train, how you eat, and what your long-term health trajectory looks like. They are precisely what a DEXA scan reveals—and why, for cancer survivors, getting baseline body composition data is not a luxury but a starting point for evidence-based recovery.
This is the same logic behind why DEXA scans reveal health risks that BMI completely misses—a problem that affects healthy adults but is amplified dramatically in cancer recovery contexts where body composition can shift dramatically while surface-level metrics appear stable.
What DEXA Scanning Actually Measures—And Why It Matters for Survivors
A clinical-grade DEXA scan produces three categories of data that are directly relevant to cancer recovery:
1. Lean Muscle Mass (Regional and Total)
DEXA measures lean tissue mass in each limb and in the trunk separately. This regional breakdown is significant for cancer survivors because treatment effects are often asymmetric. A patient recovering from breast cancer surgery may have reduced lean mass on one side. Someone who had limb-sparing surgery may show dramatic asymmetry between legs. Regional DEXA data makes these disparities visible and quantifiable.
The metric clinicians use to assess muscle adequacy relative to body size is called the appendicular lean mass index (ALMI)—total lean mass in the arms and legs divided by height squared. Low ALMI is one of the defining criteria for sarcopenia, a condition associated with falls, functional decline, and worse health outcomes across virtually every chronic disease studied. Many cancer survivors enter the sarcopenic range during treatment without knowing it.
2. Bone Mineral Density (BMD)
DEXA is the clinical gold standard for bone density measurement—the same technology used by hospitals and endocrinologists to diagnose osteoporosis. For cancer survivors, particularly those on hormone-suppressive therapies, this is not an abstract wellness metric. It is a direct measure of fracture risk.
Women on aromatase inhibitors for breast cancer are routinely counseled about bone density loss, but many do not receive baseline measurements early enough in treatment to understand how much they have lost. Men on ADT for prostate cancer face similar risks that are frequently undermonitored. Knowing your bone density—and tracking it over time—is the only way to understand whether your current exercise and nutrition approach is slowing, halting, or reversing that loss.
Our existing piece on bone density testing methods compared covers why DEXA is the measurement of choice over ultrasound and other alternatives.
3. Visceral Adipose Tissue (VAT)
Visceral fat—the fat that accumulates around abdominal organs—is metabolically distinct from subcutaneous fat and is independently associated with insulin resistance, cardiovascular disease, and systemic inflammation. Cancer survivors who gain weight post-treatment, or who experience body composition shifts from hormone therapy, often accumulate disproportionate amounts of visceral fat even when overall weight appears normal.
DEXA provides a direct estimate of VAT that no other non-invasive tool measures as accurately. This matters because visceral fat is not just a cosmetic concern during recovery—it is a metabolic signal that tells you whether your nutrition and exercise strategy is actually working at the level that matters for long-term health. For a deeper look at why this matters even for people who appear lean, see our piece on the truth about visceral fat.
The Specific Body Composition Challenges by Cancer Type
Not all cancer recoveries look the same. Here is how body composition challenges differ by treatment type:
Breast Cancer (Post-Chemotherapy and Hormone Therapy)
Breast cancer survivors face a compound challenge. Chemotherapy drives acute muscle loss and fatigue. Post-treatment hormone therapy (particularly aromatase inhibitors for estrogen receptor-positive cancers) creates an ongoing anabolic deficit that continues to erode muscle and bone for years. Many survivors also experience significant weight gain during treatment—but gain that is predominantly fat, not lean mass—leaving them in a state of sarcopenic obesity that feels counterintuitive when the scale has moved upward.
The intervention priority for most breast cancer survivors: preserve and rebuild lean mass, reduce visceral fat accumulation, and monitor bone mineral density on a defined schedule. DEXA provides the data layer to make all three trackable.
Prostate Cancer (ADT)
Androgen deprivation therapy is among the most dramatic body composition interventions a person can undergo. Within the first year of ADT, most men experience significant reductions in lean mass, increases in total fat mass, increases in visceral fat, and measurable bone density decline. These changes are not cosmetic. They are associated with cardiovascular risk, metabolic dysfunction, physical frailty, and reduced quality of life.
For men on ADT, the question is not whether body composition is changing—it is. The question is whether the exercise and nutrition strategy in place is attenuating that change. Without serial DEXA measurements, there is no objective answer to that question.
Colorectal, Lung, and Other Solid Tumor Cancers
Cachexia (cancer-related muscle wasting) is most pronounced in gastrointestinal, lung, and pancreatic cancers. Survivors of these cancers often exit treatment severely depleted in lean mass and may have significant nutritional absorption challenges that complicate rebuilding. DEXA's regional lean mass measurements help track recovery progress and identify whether targeted interventions are working.
Hematologic Cancers (Lymphoma, Leukemia, Multiple Myeloma)
Survivors of blood cancers, particularly those who underwent stem cell or bone marrow transplantation, face prolonged recovery timelines and often extended periods of immobility. Bone mineral density is a specific concern in multiple myeloma, where the disease itself can cause skeletal damage. Tracking BMD and lean mass recovery in this population requires reliable, repeatable measurement—which DEXA provides.
Where to Get a DEXA Scan Near Me: What Cancer Survivors Should Look For
If you are searching for where to get a DEXA scan near me as a cancer survivor, the key distinction to understand is the difference between a clinical DEXA performed in a hospital radiology department and a body composition DEXA performed at a specialized facility.
Hospital DEXA scans are typically ordered by physicians to assess bone density for osteoporosis diagnosis. They measure BMD but may not include full-body body composition analysis (lean mass, fat mass, VAT). Results are reported in clinical language designed for physician interpretation, and follow-up support for what to do with the data is typically absent.
Body composition DEXA facilities—like Kalos in the Bay Area—use the same clinical-grade hardware (GE Lunar or Hologic machines) but perform full-body composition scans that capture lean mass, fat mass, regional distributions, VAT, and BMD together. Critically, a quality provider pairs the scan with an in-person analysis session where the data is translated into actionable context: what it means for your recovery, where your highest-leverage opportunities are, and what the trajectory looks like over time.
For cancer survivors, that translation layer is as important as the scan itself. The data without context is just numbers. The data interpreted by someone who understands how muscle loss compounds, how bone density responds to loading, and how visceral fat responds to specific nutritional interventions—that is where recovery gets real traction.
Kalos operates three locations in the Bay Area: San Francisco, Palo Alto, and San Jose (Pruneyard). All services are HSA/FSA eligible—which matters for cancer survivors who are already managing significant healthcare costs and may be able to use pre-tax dollars to fund body composition tracking as part of their recovery protocol.
Building a Recovery Protocol Around Data: The Kalos Approach
At Kalos, we think about health goals through what we call the Performance Triangle: three vertices of Aesthetics, Longevity, and Performance. Most people come to us focused primarily on one vertex. Cancer survivors are often a notable exception—they tend to come in focused on all three simultaneously, and for good reason.
They want to look like themselves again (Aesthetics: body fat percentage, muscle mass, symmetry). They want to protect their future health (Longevity: visceral fat, bone mineral density, ALMI). And they want their body to function again—to have the energy, strength, and capacity to do things they love (Performance: strength, cardiovascular capacity, resting metabolic rate).
The encouraging truth is that for people rebuilding from a depleted state, improvements in one direction tend to improve all three. Rebuilding muscle mass improves aesthetics, reduces metabolic disease risk, and improves functional capacity simultaneously. This is not a period of trade-offs. It is a period where the right intervention compounds across all three dimensions.
The Measurement Layer
We start with a baseline DEXA scan. For cancer survivors, this scan does several things at once: it establishes where you actually are (not where you think you are based on scale weight), it identifies the highest-priority recovery targets (lean mass deficit, bone density gap, visceral fat burden), and it gives you a starting point against which every subsequent scan is compared.
Many survivors tell us the baseline scan is the first time since diagnosis that they have felt genuinely informed about their body. That information—even when the numbers are harder than hoped—tends to be experienced as empowering rather than discouraging, because it makes the path forward concrete.
The Prescription Layer
Data without prescription is a well-documented failure mode in health—what we call the prescription problem. Knowing that your ALMI is in the sarcopenic range does not automatically tell you what to do about it. Knowing your BMD T-score is -1.8 does not automatically generate a training and nutrition program.
Kalos coaches connect your DEXA metrics (the Y variables—your outcomes) to your behaviors (the X variables—your exercise, nutrition, sleep, stress management) and design the program accordingly. For cancer survivors, this often means:
- Resistance training programming prioritized above all other exercise modalities, because progressive overload is the most evidence-backed intervention for rebuilding lean mass and stimulating bone remodeling. Consistency is the 80%—the biggest determinant of results.
- Protein targets calibrated to current lean mass and recovery status. For survivors rebuilding from significant muscle loss, protein needs are elevated, and hitting those targets consistently is the nutritional intervention with the highest return on investment.
- Caloric structure designed to support muscle gain without excessive fat accumulation—a balance that requires ongoing measurement to get right, because the optimal protocol varies significantly based on where someone's body composition currently sits.
- Monthly re-scans to track whether the protocol is working. This is the piece that makes everything else more effective. When you can see, month over month, that lean mass is increasing and visceral fat is declining, the protocol is confirmed. When the data is not moving in the right direction, the protocol is adjusted before weeks become months of wasted effort.
The underlying philosophy is bottom-up rather than top-down. We are not prescribing a specific diet or training methodology and hoping it works. We are measuring what is actually happening in your body and adjusting accordingly. The data tells us what works for you—not for the average person in a clinical trial, not for the person who recovered well on keto, but for you, with your specific treatment history, your specific starting point, and your specific goals.
This same measurement-first logic applies across many contexts—it is why tracking lean mass during caloric deficits matters, and why guessing at outcomes without data leads to wasted effort and compounding problems over time.
Serial DEXA Scanning: Why Frequency Matters in Recovery
A single DEXA scan is informative. Serial DEXA scans are transformative.
The reason is that body composition changes are slow relative to the timescale of motivation. In the first month of a new resistance training and nutrition protocol, you will not see visible changes in the mirror. The scale may not move, or may move in confusing directions as hydration and glycogen levels fluctuate. This is the period when most people conclude that the approach is not working and abandon it.
DEXA captures changes that are invisible to the naked eye. A scan at month one may show 0.8 pounds of lean mass gained and 1.2 pounds of fat mass lost—changes that are physiologically significant and directionally correct but completely undetectable by any other measurement available to most people. That data point is motivating in a way that nothing else replicates. It makes the work feel real.
For cancer survivors specifically, who may be rebuilding from a more depleted starting point and against an ongoing hormonal or treatment headwind, this feedback loop is especially valuable. Progress is real but often slow. Having objective confirmation that the protocol is working—even when the changes are modest—sustains the consistency that is, by a wide margin, the biggest driver of long-term results.
Kalos members come in for monthly scans as part of their coaching membership. The scan creates the recurring data point. The analysis session after each scan is where the coaching conversation happens: what changed, why it changed, and what to adjust going forward.
Frequently Asked Questions: DEXA Scans and Cancer Recovery
Can a DEXA scan show cancer?
No. A DEXA scan is not a cancer diagnostic tool. It measures bone mineral density and body composition (lean mass, fat mass, visceral fat). It does not detect tumors or malignancies. If you have concerns about cancer screening or surveillance, speak with your oncologist about appropriate imaging modalities.
Does a DEXA scan show cancer?
No. DEXA imaging uses low-dose X-ray to differentiate bone, lean tissue, and fat. It is not designed to identify pathological tissue changes or masses. PET scans, CT scans, and MRI are the appropriate tools for oncological imaging.
Is it safe to get a DEXA scan during cancer treatment?
DEXA uses extremely low radiation doses—typically 1–6 microsieverts, which is a fraction of a chest X-ray and comparable to a few hours of normal background radiation exposure. For most patients, this is not a concern. That said, always consult with your oncologist before adding any new medical procedure during active treatment. Post-treatment, DEXA scanning is generally considered safe and appropriate.
How soon after cancer treatment can I start a body composition tracking program?
This depends on your specific treatment history and current health status, and should be discussed with your oncologist and primary care provider. Many survivors begin body composition tracking in the months immediately following treatment completion. Others wait until they are further along in recovery. The right timing is individual. What matters is that when you are ready to rebuild, you start with a data foundation rather than guessing.
Does my insurance or HSA cover DEXA body composition scans?
At Kalos, all services are HSA/FSA eligible. This means you may be able to use pre-tax health savings account dollars to fund your scans and coaching membership. Check with your HSA/FSA administrator regarding eligible expenses.
Where can I get a DEXA scan near me in the Bay Area?
Kalos has three Bay Area locations: San Francisco, Palo Alto, and San Jose (Pruneyard). Each location offers clinical-grade full-body DEXA scans with in-person analysis sessions. You can book directly at livekalos.com.
The Longer View: Why Body Composition Tracking Matters Beyond Recovery
Cancer survivorship has changed dramatically. With improving treatment outcomes across most cancer types, the majority of people diagnosed with cancer today will live for many years—often decades—after treatment. The body composition consequences of treatment do not automatically resolve with the passage of time. Muscle loss, if not actively reversed, tends to persist and compound. Bone density, if not actively defended through resistance training and adequate calcium and vitamin D intake, continues to decline. Visceral fat, absent dietary and exercise intervention, tends to accumulate further.
This is not a counsel of despair. It is the opposite. It means that the choices made in the months and years after cancer treatment have compounding positive effects—and that those choices, guided by objective data, can meaningfully alter the long-term trajectory of health, function, and quality of life.
The survivors we work with at Kalos who commit to measurement-guided recovery tend to describe a shift in how they relate to their bodies post-treatment. Many describe a sense of reclamation—moving from a period in which their body felt like something that was happening to them, to a period in which they are actively directing what happens next. The data is part of that. Knowing where you actually are, and watching objective evidence of improvement accumulate over months, changes the psychological relationship with the body in ways that feel profound.
That is, in the end, what body composition data is for. Not a number to optimize in isolation, but a feedback mechanism that makes intentional change visible, confirmable, and sustainable over the long arc of a life rebuilt after treatment.
If you are a cancer survivor in the Bay Area and want to understand where your body composition actually stands—and build a data-driven plan for rebuilding—we would welcome the conversation. Kalos has locations in San Francisco, Palo Alto, and San Jose. All services are HSA/FSA eligible. You can learn more and book a scan at livekalos.com.
Ready to measure what matters?
Book your DEXA scan today and stop guessing about your health.